Study: NCT00535743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.